Prostat Kanserinde Psikiyatrik Komorbiditeler ve Psikososyal Yük

Authors

Haşmet Sarıcı
Mustafa Samet Turgut

Synopsis

Due to increasing survival rates, prostate cancer is now regarded not only as an oncological disease but also as a chronic condition associated with significant psychiatric and psychosocial consequences. Depression, anxiety, sleep disturbances, fear of cancer recurrence, and sexual dysfunction may adversely affect patients' quality of life, treatment adherence, and clinical outcomes. In particular, androgen deprivation therapy, hormonal alterations, and the uncertainty surrounding the disease course contribute to an increased psychiatric burden. Therefore, routine screening for distress, depression, and anxiety from the time of diagnosis, early identification of high-risk patients, and timely psychiatric support are essential components of comprehensive care. Integrating pharmacological treatment with psychological and psychosocial interventions, together with a multidisciplinary care model involving urology, oncology, and psychiatry, constitutes a cornerstone of patient-centered management for individuals with prostate cancer.

References

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48.

Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356-87.

Roth AJ, Massie MJ. Anxiety and its management in advanced cancer. Curr Opin Support Palliat Care. 2007;1(1):50-6.

Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160-74.

Watts S, Leydon G, Birch B, Prescott P, Lai L, Eardley S, et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2014;4(3):e003901.

Recklitis CJ, Syrjala KL. Provision of integrated psychosocial services for cancer survivors post- treatment. Lancet Oncol. 2017;18(1):e39-e50.

Jayadevappa R, Malkowicz SB, Chhatre S, Johnson JC, Gallo JJ. The burden of depression in prostate cancer. Psycho-Oncology. 2012;21(12):1338-45.

Sharpley CF, Bitsika V, Christie DH. Psychological Distress among Prostate Cancer Patients: Fact Or Fiction? Clin Med Oncol. 2008;2:563-72.

Fang F, Keating NL, Mucci LA, Adami HO, Stampfer MJ, Valdimarsdóttir U, et al. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J Natl Cancer Inst. 2010;102(5):307-14.

Recklitis CJ, Lockwood RA, Rothwell MA, Diller LR. Suicidal ideation and attempts in adult survivors of childhood cancer. J Clin Oncol. 2006;24(24):3852-7.

Pirl WF, Siegel GI, Goode MJ, Smith MR. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology. 2002;11(6):518-23.

Green TP, Saavedra-Belaunde J, Wang R. Ejaculatory and Orgasmic Dysfunction Following Prostate Cancer Therapy: Clinical Management. Med Sci (Basel). 2019;7(12).

Chung E, Brock G. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J Sex Med. 2013;10 Suppl 1:102-11.

James C, Brunckhorst O, Eymech O, Stewart R, Dasgupta P, Ahmed K. Fear of cancer recurrence and PSA anxiety in patients with prostate cancer: a systematic review. Support Care Cancer. 2022;30(7):5577-89.

Mravec B, Tibenský M, Horváthová Ľ. Psychoneuroimmunology of Cancer - Recent Findings and Perspectives. Klin Onkol. 2018;31(5):345-52.

Nilsson R, Næss-Andresen TF, Myklebust T, Bernklev T, Kersten H, Haug ES. Fear of Recurrence in Prostate Cancer Patients: A Cross-sectional Study After Radical Prostatectomy or Active Surveillance. Eur Urol Open Sci. 2021;25:44-51.

De Sousa A, Sonavane S, Mehta J. Psychological aspects of prostate cancer: a clinical review. Prostate Cancer Prostatic Dis. 2012;15(2):120-7.

De Sousa A, Sonavane S, Mehta J. Psychological aspects of prostate cancer: a clinical review. Prostate Cancer and Prostatic Diseases. 2012;15(2):120-7.

Nead KT, Sinha S, Yang DD, Nguyen PL. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis. Urol Oncol. 2017;35(11):664.e1-.e9.

Alwhaibi A, Alsanea S, Almadi B, Al-Sabhan J, Alosaimi FD. Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management. Aging Male. 2022;25(1):101-24.

Sparasci D, Napoli I, Rossi L, Pereira-Mestre R, Manconi M, Treglia G, et al. Prostate Cancer and Sleep Disorders: A Systematic Review. Cancers. 2022;14(7):1784.

Chen W, Chen Y, Xiao H. Existential Distress in Cancer Patients: A Concept Analysis. Cancer Nurs. 2022;45(2):E471-e86.

Ownby KK. Use of the Distress Thermometer in Clinical Practice. J Adv Pract Oncol. 2019;10(2):175-9.

Chambers SK, Zajdlewicz L, Youlden DR, Holland JC, Dunn J. The validity of the distress thermometer in prostate cancer populations. Psychooncology. 2014;23(2):195-203.

Cutillo A, O’Hea E, Person S, Lessard D, Harralson T, Boudreaux E. The Distress Thermometer: Cutoff Points and Clinical Use. Oncol Nurs Forum. 2017;44(3):329-36.

Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-13.

Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-70.

Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-7.

van Andel G, Bottomley A, Fosså SD, Efficace F, Coens C, Guerif S, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44(16):2418-24.

Mundle R, Afenya E, Agarwal N. The effectiveness of psychological intervention for depression, anxiety, and distress in prostate cancer: a systematic review of literature. Prostate Cancer Prostatic Dis. 2021;24(3):674-87.

Chambers SK, Pinnock C, Lepore SJ, Hughes S, O’Connell DL. A systematic review of psychosocial interventions for men with prostate cancer and their partners. Patient Educ Couns. 2011;85(2):e75-88.

Chambers SK, Hyde MK, Smith DP, Hughes S, Yuill S, Egger S, et al. New Challenges in Psycho-Oncology Research III: A systematic review of psychological interventions for prostate cancer survivors and their partners: clinical and research implications. Psychooncology. 2017;26(7):873-913.

Regan TW, Lambert SD, Girgis A, Kelly B, Kayser K, Turner J. Do couple-based interventions make a difference for couples affected by cancer? A systematic review. BMC Cancer. 2012;12:279.

Roth AJ, Rosenfeld B, Kornblith AB, Gibson C, Scher HI, Curley-Smart T, et al. The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer. Cancer. 2003;97(11):2910-8.

Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK, et al. Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. J Clin Oncol. 2016;34(16):1905-12.

Chambers SK, Hyde MK, Smith DP, Hughes S, Yuill S, Egger S, et al. New Challenges in Psycho-Oncology Research III: A systematic review of psychological interventions for prostate cancer survivors and their partners: clinical and research implications. Psycho-Oncology. 2017;26(7):873-913.

Faller H, Schuler M, Richard M, Heckl U, Weis J, Küffner R. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol. 2013;31(6):782-93.

Published

November 17, 2026

License

License